BriaCell Therapeutics (NASDAQ:BCTX) focuses on the development of targeted and effective immunotherapies for cancer. The cornerstone of their operations is their novel cancer vaccine technology, which aims to harness the patient's immune system to combat cancer cells specifically and effectively. BriaCell's leading project, a clinical stage breast cancer treatment, showcases their commitment to advancing cancer therapy through innovative research and development. Their objective is to transform cancer treatment by developing therapies that are not only potent but also less toxic and more tolerable for patients, aiming to improve quality of life alongside extending survival rates.